CAR T-Cell Therapy: Unleashing Your Body's Army Against Cancer and Beyond

How reprogrammed T cells become living medicines. In clear, science-first episodes, we trace collection → engineering → infusion, highlight successes in B-cell cancers (CD19, BCMA), unpack risks (CRS, ICANS), and preview what’s next—off-the-shelf/allogeneic CARs, safety switches, and solid-tumor strategies. Subscribe for translational takeaways you can trust.